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Abstract: Alzheimer’s disease (AD) is a leading cause of chronic dementia in the US. Its 
incidence is increasing with an attendant increase in associated health care costs. Since its ﬁ  rst 
description in a patient by Dr. Alois Alzheimer over a century ago, a large body of biomedical 
literature has established a detailed clinical and molecular proﬁ  le of this disorder. Amyloid β 
peptide (Aβ; a 39–42 amino acid molecule) is the major component of senile plaques, the lesions 
that are one of the pathologic hallmarks of AD (Wong et al 1985). Although many aspects of 
the biology of amyloid β have been investigated, several fundamental questions about how this 
peptide causes AD neuropathology remain unanswered. The key question is: How is Aβ toxic 
to cerebral neurons? Because plaques are extra-neuronal deposits, it is difﬁ  cult to imagine a 
structural basis for their toxicity. As an interesting contrast the other pathognomonic feature 
of AD, neuroﬁ  brillary tangles, are intra-axonal structural anomalies that are composed of the 
hyperphosphorylated microtubule associated (MAP) protein, tau. This review will assess the 
current thinking that relates to a recent hypothesis of Aβ toxicity. In 1992, Hardy and Higgins 
reported ﬁ  ndings that suggested a new and intriguing possibility. These authors found that Aβ 
peptides disrupt Ca2+ homeostasis in neurons and increase intracellular Ca2+ [Ca2+]i. This was 
corroborated by Mattson and his colleagues who demonstrated that Aβ exposure to human 
cortical neurons raised [Ca2+]i (Mattson, Cheng et al 1992); (Hardy and Higgins 1992). Finally, 
Nelson Arispe’s group at the NIH speciﬁ  cally investigated the possibility that Aβ peptides might 
function like Ca2+ ion channels (Arispe et al 1993). This and several subsequent studies have laid 
the foundation for a novel idea: “Aβ peptides are, in part, toxic to neurons because they form 
aberrant ion channels in neuronal membranes and thereby disrupt neuronal homeostasis”. In this 
review we shall critically examine this theory in light of classic and contemporary literature.
Keywords: Alzheimer’s disease, Aβ channels, ion channel hypothesis
Introduction
Dementia of the Alzheimer’s type
Dr. Alois Alzheimer, a Bavarian psychiatrist, interviewed a patient in 1901. This was 
a 51 year-old woman who had declining cognitive abilities and memory. Her neu-
rological evaluation by Alzheimer, Emil Kraeplin and others ﬁ  rst helped deﬁ  ne this 
clinicopathological syndrome of late-life mental decline. However, it was much later 
(in the decade of the 1960s) that the work of Tomlinson et al established Alzheimer’s 
disease (AD) as the most common form of senile dementia (Tomlinson et al 1968, 
1970). Today, with exponential advances in ﬁ  elds such as neurology, pathology, 
biophysics, computer modeling, molecular genetics, and immunochemistry, many 
aspects of AD, its etiology and underlying mechanisms have been discovered. 
However, a robust scientiﬁ  c debate still continues about the fundamental mechanis-
tic details of the disorder. It’s not surprising therefore, that a cure has not yet been 
discovered, even in the face of an increasing health care burden and near epidemic Neuropsychiatric Disease and Treatment 2007:3(5) 598
Shirwany et al
proportions of the epidemiology of the disease in the United 
States and across the western hemisphere.
Amyloid β metabolism
How Aβ accumulates in the brain is a complex narrative. 
Brieﬂ  y, a locus on the human chromosome 21 (21q21.3) 
encodes a transmembrane glycoprotein called APP (Amyloid 
Precursor Protein). This 695–770 amino acid peptide does 
not have an established physiological function. As a conse-
quence of metabolic processing, this molecule can generate 
both amyloidogenic (ie, having a propensity to produce Aβ) 
and non-amyloidogenic products (Fraser et al 1997). If APP 
is proteolytically cleaved by the enzyme α-secretase, the 
neuroprotective fragment sAPPα (for secreted APPα) is 
produced and Aβ formation is prevented (Pearson and Peers 
2006). In contrast, if sequential cleavage by β- and then 
γ-secretases predominates, Aβ is formed. β- and γ-secretase 
cleavages are constitutive events in that Aβ is detectable in 
the pico-to-nanomolar range in normal brains (Haass et al 
1992; Seubert et al 1993; Wilson et al 1999). However, 
relatively recent research has shown that β-secretase has 
optimal activity at a pH of ~4.0 (Lin et al 2000). The enzyme 
is usually located on the cell surface where the ambient pH 
is much higher (~7) forcing it to remain dormant (Lin et al 
2000; He et al 2007). The proteolysis of APP by β-secretase 
necessitates internalization of both molecules through an 
endocytic mechanism into lysosomes. Here, at more optimal 
pH, β-secretase then cleaves APP and these intracellular 
sites become the major locations for the production of Aβ 
(Koo and Squazzo 1994; Cook et al 1997; Hartmann et al 
1997). Speciﬁ  cally, APP proteolysis following internaliza-
tion occurs in:
1.  The Endoplasmic Reticulum: This is the major site of 
Aβ1–42 synthesis (Wilson et al 1999).
2.  The Trans-Golgi Network: Where most of the Aβ1–40 is 
generated (Wilson et al 1999).
3.  The Endosomal/Lysosomal system: This contributes only 
minor amounts of Aβ (Wilson et al 1999).
There may be two distinct fates of secreted Aβ pep-
tides. Indirect evidence suggests that in the normal brain 
these peptides are cleared from the extracellular space. In 
humans who inherit the Apolipoprotein E4 (ApoE4) allele 
(and this is known to increase their risk of developing AD), 
there is no apparent increase in Aβ production (eg, plasma 
Aβ levels in these subjects remain normal). However, in 
human neuropathological studies as well as mouse models, 
inheritance of ApoE4 causes a rise in the steady state levels 
of Aβ in the brain. This either happens by an enhancement 
of the ﬁ  brillogenic potential or be decreasing the clearance 
of Aβ (Selkoe 2001).
Metabolic labeling studies have also demonstrated 
that newly formed Aβ is rapidly turned over in the brain 
and that Aβ-degrading proteases help regulate its levels in 
the brain (Savage et al 1998). These enzymes are largely 
serine or metalloproteases and include insulin degrading 
enzyme (IDE), neprilysin (NEP), plasmin, plasminogen 
activator (uPA/tPA), endothelin enzyme-1 and matrix 
metalloproteinase-9 (MMP-9) (Selkoe 2001).
Reports have suggested that their may be two distinct 
pools of Aβ. The intracellular pool remains unsecreted and 
is possibly degraded while the secreted pool, via the Golgi 
and post-Golgi vesicles and the Endosomal/Lysosomal sys-
tem is secreted and this fraction is destined to contribute to 
the formation of senile plaques in the brains of AD patients. 
The peculiarities of the aging brain that predispose neurons 
in general to this fate of Aβ and to speciﬁ  c populations 
within the cortex, are not well understood and might hold 
the key to the overarching causality of AD (Wild-Bode et al 
1997; Wilson et al 1999). Figures 1, 2 and 3 schematically 
summarize APP metabolism, Aβ synthesis and the ultimate 
fates of these peptides.
Aside from senile plaques, the other characteristic 
lesions of AD are neuroﬁ  brillary tangles which are intra-
cellular structures composed of hyperphosphorylated tau 
protein. The ongoing debate in AD research is the connec-
tion between these neuron-associated anomalies and the 
ultimate emergence of the Alzheimer’s clinical syndrome 
(Blessed et al 1968; Neve et al 1990; Katzman and Saitoh 
1991). Amyloid plaques are not simple structures composed 
of a single molecular population (ie, Amyloid β). In fact, 
a variety of substances have been found in these lesions. 
These include:
1.  Proteoglycans, including heparan, chondroitin, keratin 
and dermatan sulphate proteoglycans.
2. Inﬂ  ammatory molecules, including acute phase proteins, 
cytokines, chemokines, complement proteins, comple-
ment inhibitor.
3.  Serum related molecules, including amyloid P compo-
nent.
4.  Metal ions, including Fe, Cu, Zn.
5.  Amyloidogenic related molecules, including non-Aβ 
component of AD amyloid (NAC) that represents 
about 10% of the non-SDS-soluble material in amyloid 
plaques. Apolipoprotein E, low density lipoprotein 
receptor-related protein], cystatin-C (gamma-trace 
peptide).Neuropsychiatric Disease and Treatment 2007:3(5) 599
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6.  Protease and clearance related elements, including 
α1-antichymotrypsin, α1-trypsin, lysosomal proteinases, 
ubiquitin, α2-macroglobulin.
7.  Antioxidant defense proteins, including ferritin, ceru-
loplasmin, SOD-1 and SOD-2, HO-1 and possibly 
catalase.
8.  Cholinesterases, including acetylcholinesterase and 
butyrylcholinesterase.
9.  Other proteins, including the multifunctional clusterin 
(Apo-J, SP-40).
[For an excellent and very comprehensive overview of 
plaque composition and chemistry, see Atwood and Martins 
(2002)].
This classical description of AD pathogenesis (the “amy-
loid hypothesis of AD”) has certain important caveats. Data 
has shown that the mature aggregated form of Aβ (amyloid 
ﬁ  brils) which are observed in cortical areas of AD patients, 
may not be the direct causative agents of neuronal degen-
eration and death (Eliezer 2006). In fact, typical amyloid 
deposits are absent in certain forms of AD and even when 
they are evident, may not be toxic or even help in cell survival 
(Tompkins and Hill 1997; Arrasate et al 2004). This deviation 
from conventional wisdom has, in part, led to the emergence 
of an alternative theory which is sometimes referred to as 
the “oligomer hypothesis of AD”. This theory posits that 
while mature amyloid ﬁ  brils may not themselves be toxic, 
some species formed during the process of ﬁ  brillar assembly 
might be the primary toxic entities. These molecules seem to 
be generated in the synthesis of amyloid ﬁ  brils and are Aβ 
oligomeric structures (Caughey and Lansbury 2003; Walsh 
and Selkoe 2004).
Physiology of Aβ peptides
Many studies suggest that Aβ might have a physiological 
function. In fact, Aβ peptide can be detected in human cere-
brospinal ﬂ  uid (CSF) in a variety of isotypes ranging in length 
from 38 to 42 amino acids. Typically, in healthy individu-
als, the predominant form of Aβ is Aβ1–40 (about 90% of the 
total amount) while Aβ1–42 represents approximately a 10% 
fraction. This ratio is dramatically altered in AD with about 
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Figure 1 APP proteolytic processing and major fates of the amyloid β (Aβ) fragment. Sequential cleavage by β-secretase (BACE-1) followed by γ-secretase [containing 
Presenilin 1 and 2 (PS1/2)] generates Aβ. This fragment has several fates. (a) It can aggregate and accumulate as extraneuronal plaques which characterize Alzheimer’s 
dementia. (b) It can be cleared from the extracellular space (a mechanism that may be altered in AD brains). (c) It can be degraded by a variety of proteases such as Insulin 
Degrading Enzyme (IDE), Neprilyisn (NEP), Plasmin, Plasminogen Activator (uPA/tPA), Endothelin Enzyme-1 or Matrix Metalloprotease-9 (MMP-9). Hypothetically, at least, it 
might return to the plasma membrane and insert in oligomer form as an ion channel. γ-secretase cleavage is also thought to liberate an intracellular domain (AICD) which 
may inﬂ  uence gene transcription.Neuropsychiatric Disease and Treatment 2007:3(5) 600
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even representation of both isotypes (Mehta et al 2001; Plant 
et al 2003). Thus Aβ toxicity might represent a disturbance 
of normal function.
Evidence for a physiologic role
Aβ peptide appears to be involved in synaptic signaling 
(Pearson and Peers 2006). In 2003, Kamenetz et al reported 
that Aβ synthesis was increased when hippocampal neurons 
were activated by evoked potentials. This seemed to occur 
through increased APP trafﬁ  cking toward β-secretase sites 
on the cell membrane which, in turn, increased the probability 
of β-secretase cleavage (Kamenetz et al 2003). In addition 
to increased Aβ production, other APP fragments were also 
liberated in greater numbers. It has been hypothesized that 
this scenario is a negative feedback mechanism where Aβ 
can (which is also known to inhibit synaptic activity) protect 
against unregulated signaling and consequent excitotoxic-
ity at the synapse. In fact, Kamenetz observed that when 
γ-secretase activity was blocked, the frequency of excitatory 
postsynaptic currents (EPSC) was increased. In addition, an 
earlier study has also shown that kainate-induced seizures 
are potentiated in APP-knockout mice (Steinbach et al 1998). 
Neuronal activity has been shown to modulate both the basal 
secretion of Aβ as well as the upregulated synthesis noted in 
genetic APP mutations (such as the Swedish mutation) that 
are causally linked to certain familial forms of AD. Further 
and somewhat indirect evidence that supports a physiologic 
role for Aβ, is the mechanism through which benzodiaz-
epines (by enhancing inhibitory neurotransmission) and 
NMDA receptor antagonists (eg, Memantine) act to slow 
the cognitive decline of AD (Fastbom et al 1998; Winblad 
and Poritis 1999). More indirect evidence that supports this 
idea is the enhancement of Ca2+ and K+ ion channel activity 
that has been observed in rodent cortical neuronal cultures 
upon application of soluble forms of Aβ (Price et al 1998; 
Ramsden et al 2002). Recently it has also been reported that 
NMDA-receptor stimulation also upregulates APP synthesis 
with a concomitant increase in Aβ levels (Lesne et al 2005). 
As was described in a previous section, sequential cleavage 
of APP by β- and then γ-secretases creates Aβ fragments. 
The discovery that the Aβ1–42 fragment was the major com-
ponent of plaques in AD led to an interest in developing 
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Figure 2 Sequential cleavage by β-secretase and γ-secretase releases Aβ fragment of varying length. β-secretase cleavage has to occur following internalization of APP-
enzyme complex at pH values around 4.0 in cytosolic locations.Neuropsychiatric Disease and Treatment 2007:3(5) 601
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pharmaceutical inhibitors of these enzyme complexes. Some 
studies have alluded to the toxicity of such inhibitors. For 
example, Plant et al (2003) have reported that inhibition of 
β- or γ-secretase in neurons can compromise cell viability. 
These observations also support a physiological function for 
Aβ peptides. Indeed, in APP-knockout mice neurological 
and behavioral deﬁ  cits are noted even though neurons can be 
harvested from pre-natal animals and successfully cultured 
suggesting that even though APP (and possibly Aβ) might 
have a functional role, they are not mandated for survival 
(Zheng et al 1995; Harper et al 1998; White et al 1998).
Because APP has so many proteolytic products, a com-
pelling argument can be made that APP-processing is also 
a physiological process and that Aβ is part of this complex 
system. When the delicate balance of this process is dis-
turbed, toxic forms of Aβ proliferate leading to neuronal 
degeneration (see below).
The toxicity of Aβ peptides
It is now widely accepted that the accumulation of Aβ in 
cerebral centers involved in cognition and memory is a 
common feature of AD pathology. These areas are mainly 
the temporoparietal and frontal cortices, the cingulate 
gyrus and hippocampus (Wenk 2003, 2006). Glenner ﬁ  rst 
identiﬁ  ed Aβ in meningovascular amyloid deposits in AD 
patients (Glenner and Wong 1984). Subsequently several 
other laboratories reported ﬁ  nding this peptide in senile 
plaques (Gorevic et al 1986; Selkoe et al 1986; Mann et al 
1996) The composition of plaques is attributed largely 
to the Aβ1–42 form of amyloid β (Dickson 1997; Selkoe 
2001). However, which form of Aβ is most critical to AD 
pathogenesis remains the subject of some debate. One of the 
controversies is that the major component of both diffuse 
and senile plaques is the Aβ1–42 form and yet this 42-amino 
acid fragment of APP is a quantitatively minor product 
of processing. In addition to Aβ1–42, the amino terminus 
truncated form Aβx–42 is also found in plaques (Iwatsubo 
et al 1994; Gravina et al 1995). The heterogeneity of Aβ 
species is principally linked to where the fragment is termi-
nated. Termination at amino acid 40 produces the slightly 
shorter Aβ1–40, while at 42, the more amyloidogenic Aβ1–42 
is formed. In addition, variant splicing of the N-terminus 
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Figure 3 APP internalization and generation of Aβ. APP is trafﬁ  cked through constitutive secretory pathways, undergoes post-translational modiﬁ  cation and ultimately 
locates to the plasma membrane. Poorly understood mechanisms/signals then effect internalization/endocytosis of APP to intracellular sites where optimum pH exists for 
activation of is β-secretase (BACE-1) that process APP.Neuropsychiatric Disease and Treatment 2007:3(5) 602
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produces the Aβx–40 and Aβx–42 fragments (Wild-Bode 
et al 1997).
These facts suggest that the central anomaly in AD 
might be an alteration of the ratio between the normally 
predominant form (Aβ1–40) and Aβ1–42. Aβ has intriguingly 
been observed not only in the classic lesions of AD but also 
in diffuse plaques that are recognized by amyloid antibod-
ies but do not take on classic amyloid stains (Levites et al 
2006). Other Aβ species (most prominently Aβ1–40 and 
Aβx–40) are also present, especially in cerebrovascular amy-
loid deposits that are notably seen in the aging brain (Golde 
et al 2000). Soluble oligomers referred to as Aβ-derived 
diffusible ligands (ADDLs) are also capable of disturb-
ing neuronal function in rodents and they are observed to 
accumulate in the brains of AD patients (Klein et al 2004; 
Walsh and Selkoe 2004). In contrast Aβ can be detected 
in human brains not affected by AD. For example, Aβ can 
be measured in the CSF of non-demented human subjects 
(Aβ1–42) and in the media of normal neuronal cultures (iso-
form not identiﬁ  ed) (Haass et al 1992; Tamaoka et al 1997). 
Thus, it is not merely the presence of any Aβ isoform that 
pushes the brain toward cognitive decline. More speciﬁ  -
cally the relative levels of Aβ1–42 predispose to neuronal 
dysregulation and dementia (Younkin 1998). In addition, 
Aβ1–42 has been shown to accumulate as amyloid ﬁ  brils 
as well as soluble intermediates more readily than Aβ1–40 
(Jarrett et al 1993; Levites et al 2006). Exogenous Aβ causes 
neuronal degeneration in primary cultured neurons (Yankner 
et al 1990). Exogenous Aβ causes the same phenomenon 
when injected into the brains of adult rats (Kowall et al 
1991; De Ferrari et al 2003; Morgan et al 2004; Reyes et al 
2004). Synthesized Aβ peptides cause both trophic and toxic 
changes in cultured neurons (Whitson et al 1989; Koh et al 
1990; Yankner et al 1990; Mattson et al 1992; Lorenzo and 
Yankner 1994). Research has also suggested that Aβ might 
not be directly toxic itself. It may transform the neuron into 
becoming more susceptible to other background noxious 
agents. For example, these might be excitatory amino acids 
or free radicals (Koh et al 1990; Miranda et al 2000). Aβ’s 
toxicity also appears to be related to its aggregation state. 
Thus, aggregated forms of Aβ are toxic while solubilized 
(generally newly synthesized) forms are not (Pike et al 
1993). Talafous has suggested that the monomeric form 
of Aβ (in α-helix conformation) is neurotrophic and that 
when this changes to the oligomeric, β-sheet conformation, 
the peptide becomes neurotoxic. This hypothesis needs 
further evaluation (Talafous et al 1994). In an interesting 
study, Roher and colleagues (1996) were able to quantify 
the proportion of Aβ monomers, dimmers and trimers as 
55:30:15, respectively. Further, monomers and dimmers 
exhibited toxicity in culture only in the presence of microg-
lia. Without these cells, even a 10-fold increase in dose has 
failed to exhibit toxic effects. Therefore it is now widely 
held that the toxicity of Aβ peptides is, in part, related to 
their aggregation state. This elegantly explains the various 
deviations in published literature discussed here (Morgan 
et al 2004).
Intraneuronal Aβ
Another intriguing aspect of Aβ species is that they are 
also synthesized in subcellular compartments such as the 
endosomes and lysosomes, particularly but not exclusively 
in non-neuronal cell systems (Haass et al 1992; Wilson et al 
2002). Both major forms of Aβ peptide appear to be synthe-
sized in speciﬁ  c subcellular locations. Aβ1–40 is formed in the 
trans-golgi network (TGN) while Aβ1–42 is produced in the 
endoplasmic reticulum/immediate compartment (ER/IC). 
The Aβ1–42 is retained inside the cell in both neurons and 
other cell types and is therefore not destined to be secreted 
into the extracellular matrix with the possible fate of becom-
ing part of a plaque deposit (Cook et al 1997; Hartmann et al 
1997; Wild-Bode et al 1997; Xu et al 1997; Skovronsky et al 
1998; Greenﬁ  eld et al 1999). Are these intracellular (or with 
more relevance, intraneuronal) Aβ fractions toxic as well? 
There is mounting evidence that suggests this might be the 
case. The following is a selection of current literature sup-
porting this idea:
1.  Takashi and colleagues (2002) have observed that intra-
neuronal Aβ accumulates in multi-vesicular bodies and 
late endosomes in both the brains of AD patients as well 
as APP transgenic mice. In a more recent study, Oakley 
and colleagues (2006) have found that Aβ accumulates 
near the axon hillock in APP/PS1 double transgenic mice 
and suggest that this might potentially interfere with 
axonal transport and possibly action potential generation 
as well.
2.  More directly, investigations of intracellular Aβ have 
shown that the peptides can reduce presynaptic and post-
synaptic markers, cause abnormal neuronal morphology 
and elevation of p25 [activator of cyclin-dependent kinase 
5 (cdk5); an early marker of neuronal degeneration] 
(Urbanc et al 2002; Cruz and Tsai 2004).
3.  It has also been suggested that an over accumulation 
of Aβ1–42 inside the neuron causes lysis and amyloid 
plaques represent the sites where this happens. In other 
words, these lesions are the remnants of lysed neuronal Neuropsychiatric Disease and Treatment 2007:3(5) 603
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populations (Wirths et al 2004). This hypothesis is not 
without some empirical support. For example:
      a.    In neurons in culture, over time there is an increase in 
intracellular Aβ1–42 as well as an increase in the Aβ1–42/
Aβ1–40 ratio. This increase is higher than secreted Aβ 
(Turner et al 1996; Skovronsky et al 1998).
      b.   As noted above, neuroﬁ  brillary tangles are the other 
hallmark lesion of AD and are composed of hyper-
phosphorylated tau protein. The protein is observed 
to be about 20–25 nm wide with periodic twisting 
and is therefore also referred to as paired helical ﬁ  la-
ments (PHF). PHF accumulation is one of the earliest 
events in AD pathology. Intracellular Aβ appears to 
accumulate even before PHF becomes detectable and, 
more interestingly, declines as cognitive dysfunction 
progresses and plaque deposition accelerates (Gouras 
et al 2000; Fernandez-Vizarra et al 2004).
     c.   In several AD animal models, intraneuronal Aβ 
correlates with early synaptic dysfunction prior to 
plaque deposition and the appearance of tangles 
(Takahashi et al 2002; Wirths et al 2002; Oddo et al 
2003; Schmitz et al 2004).
      d.   In animal models in which βAPP, Presenilin-1 (PS1) or 
Presenilin-2 (PS2) genes are mutated, the intracellular 
Aβ1–42/Aβ1–40 ratio is increased (Wang et al 2006).
Overall, these tantalizing pieces of evidence strongly 
suggest that Aβ peptides are not an isolated extracellular 
phenomenon. Instead, there seems to be a dynamic rela-
tionship between two pools of Aβ, one inside and the other 
external to neurons in critical brain regions. Further details 
of the temporal relationship between these two pools needs 
further study and should reveal fascinating insights into AD 
pathology.
Aβ triggers apoptosis or necrosis?
Imaging and molecular studies on human brains affected by 
AD show ample evidence that there is both focal and diffuse 
degeneration and loss of neuronal tissue. What is less clear 
is whether this represents necrosis of cells in the brain or a 
manifestation of apoptosis. For example Behl and colleagues 
(1994) observed that PC12 cells when exposed to Aβ (25–35) 
underwent necrosis (electron microscopy data). In addition 
and quite interestingly, evidence has been found in humans 
carrying the presenilin-1 mutation E280A, that neurons 
undergo necrosis (Velez-Pardo et al 2001). In contrast, sev-
eral other recent studies seem to implicate apoptosis as the 
underlying mechanism of neural dysfunction and loss. For 
example, increased expression of p53 (a widely used marker 
of apoptotic DNA damage) was noted in neurons exposed 
to Aβ (Copani et al 2002). More speciﬁ  cally, studies have 
shown that the expression of the pro-apoptotic effector bax is 
upregulated and the anti-apoptotic molecule, bcl2 is decreased 
in AD (Paradis et al 1996; Tamagno et al 2003). Tamagno’s 
group have also published results that demonstrate recruit-
ment of p53 and cytosolic release of cytochrome-c as well as 
activation of caspase-3 (all excellent markers of apoptosis), 
in Aβ exposed neurons (Tamagno et al 2003).
Another confounding aspect of deciding between which 
of these two phenomena dominate in a given situation is that 
the distinction between the two has become increasingly 
less certain. This is evident, for example, from a sharing of 
signaling pathways between the two processes (McHugh and 
Turina 2006). In addition, one of the best studied AD causing 
gene mutations is in the Presenilin-1 locus on chromosome 
14. This has been shown to increase neuronal vulnerability 
to kainic-acid induced necrosis by one of this review’s 
co-authors (Guo et al 1999). Furthermore, the intensity of 
the same type of insult can become decisive in whether 
apoptosis or necrosis will supervene (Denecker et al 2001). 
Other situational peculiarities also seem to make a difference. 
For example a depletion of cellular ATP has been shown to 
shift the outcome from apoptosis to necrosis (Eguchi et al 
1997; Leist et al 1997).
Neuronal Ca2+ homeostasis
and the role of amyloid β
From the evolutionary standpoint, Ca2+ homeostasis is 
affected through an ancient cellular system of ion channels, 
intracellular stores and signaling cascades. This is not surpris-
ing because the ion is intimately involved in a wide range 
of physiological reactions and processes (Verkhratsky 1998; 
Toescu and Verkhratsky 2000). This system utilizes the very 
large transmembrane Ca2+ gradient which far exceeds that of 
all the other physiologically relevant ions. Therefore even 
small changes in Ca2+ conductance in the cell membrane 
result in large effects on intracellular Ca2+ concentrations 
[Ca2+]i. Thus the system is one with a very high signal-to-
noise ratio.
The inﬂ  ux of Ca2+ ions through voltage-gated plasma mem-
brane channels (VDCC) is a critical signal in neurotransmitter 
release from the presynaptic terminal as well as subsequent 
responses by the postsynaptic cell (Yuste et al 2000; Burnashev 
and Rozov 2005; Hartmann and Konnerth 2005). The resting 
neuron maintains a large Ca2+ gradient between the extracel-
lular space and the cytosol. Speciﬁ  c signals such as voltage 
change or ligand-receptor interactions, effect opening of a Neuropsychiatric Disease and Treatment 2007:3(5) 604
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variety of Ca2+ channels. These conduits are found both on 
the plasma membrane (the L, N and some R-type channels) 
as well as on the surface of intracellular Ca2+ stores (eg, the 
RyR channels on the SER) (Akita and Kuba 2000; Vanter-
pool et al 2005). These channels cause a dramatic increase in 
intracellular Ca2+ concentration ([Ca2+]i) and are (depending 
on the magnitude of the Ca2+ transient) evoke complex buff-
ering systems {eg, Ca2+ buffering proteins, smooth ER Ca2+-
ATPases (SERCA), mitochondrial Ca2+ uptake, plasmalemmal 
Ca2+-ATPases (PMCA) and the Na+/Ca2+ exchanger}. These 
corrections tend to restore [Ca2+]i to resting levels (Wuytack 
et al 2002; Buchholz et al 2007). The transient rise in [Ca2+]i 
under normal conditions is very short lived (typically on the 
order of seconds to minutes). This rise in Ca2+ in turn sets up 
downstream signaling for a variety of cellular functions such 
as neurite growth, synaptogenesis, synaptic transmission and 
plasticity and cell survival (Mattson 2007). However in patho-
logical states (such as AD) and even in normal aging, Ca2+ 
ﬂ  ux and cellular load is poorly controlled. The mechanisms 
of these disturbances are varied and include oxidative stress 
(particularly membrane associated oxidative stress; MAOS) 
and disturbed energy metabolism (Mattson 2007). MAOS 
impairs the function of ion-motive ATPases and glutamate 
and glucose transporters and this in turn promote membrane 
depolarization, further Ca2+ inﬂ  ux and glutamate excitotoxic-
ity through over activation of glutamate receptors (Mattson 
1998; Arundine and Tymianski 2004; Mattson 2007). Table 1 
provides a summary of native neuronal ion channels.
Why is Ca2+ so critical to the neuron? More speciﬁ  cally, 
why is the aging brain of an AD patient more sensitive to Ca2+ 
perturbations in general and the impact of Aβ in particular? 
These fascinating questions have direct bearing if one is to 
be convinced that abnormal ion channels (especially those 
showing selectivity for cations like Ca2+) might be part of 
the toxic mechanism behind AD pathology. In brief the fol-
lowing summary of investigation helps to understand why 
this might be the case:
1.  Evidence suggests that larger Ca2+-dependent after 
hyperpolarization and increased activity of L-type Ca2+ 
channels occurs in the aging brain.
2. Increased  Ca2+ release from intracellular stores appears 
to contribute to cell death and vulnerability in several 
models of neuronal toxicity.
3.  Some AD-associated gene mutations (eg, Presenilin 
mutations) appear to alter the expression of intracellular 
Ryanodine receptors (RyR) which mediate Ca2+ release 
from intracellular stores.
4.  In hippocampal slices from the aging rat brain, 
Ca2+-induced Ca2+ release (CICR) seems to be upregu-
lated.
[For a review see Thibault et al 2007].
In view of the signiﬁ  cant correlation between intra-
neuronal accumulation of Aβ and the critical role of Ca2+ 
ion channels in subcellular structures (such as the ER), it 
is seductive to think that Aβ’s ion channel forming ability 
might also extend to intracellular sites. Speciﬁ  cally, what 
if these peptides were also capable of inserting as aberrant 
channels in intracellular Ca2+ stores? Could this possibility 
amplify the perturbations Aβ peptides can induce on the 
surface of neurons? Not only is this a fascinating idea, it is 
also very challenging to prove. Some of the difﬁ  culty stems 
from the technical issues of electrophysiological recordings 
from intracellular organelles. In fact, it was not until 1997 
that Jonas and Kaczmarek reported successful results of 
patch-clamp recordings from intracellular membranes from 
a variety of cell types including Chinese hamster ovary cells, 
the giant presynaptic terminal of the squid and rat microglial 
cells. Prior to this report, electrophysiological recordings 
from intracellular structures were limited to artiﬁ  cial lipid 
bilayers or preparations of isolated organelles. However, in 
addition to the technical difﬁ  culty of achieving consistent 
giga-ohm seal patch-clamps on intracellular membranes, 
the additional difﬁ  culty in getting meaningful electrophysi-
ological data is that the ionic composition of intracellular 
compartments is not objectively measurable in such experi-
mental models. Thus, short of creating an excised patch and 
then studying ionic ﬂ  ow across (for instance in an inside-
in conﬁ  guration) the subcellular membrane, convincing 
Table 1 Summary of native neuronal ion channels
Voltage-gated Ca2+ channels on the 
cell surface (VOCCs)
These channels are one of the 
two main routes of Ca2+ entry 
into the cell and are regulated 
by changes in membrane voltage 
(Hofmann et al 1994; Hollmann 
and Heinemann 1994; Catterall 
1998).
Ionotropic Ca2+ channels This is the other main variety 
of Ca2+ channels expressed on 
the neuronal membrane and 
are gated by binding of speciﬁ  c 
agonists (eg, ATP) (Gever et al 
2006).
Intracellular Ca2+ channels This class of Ca2+ channels is 
found on the membranes of 
intracellular Ca2+ stores, ie, 
endoplasmic reticulum (ER) 
(Furuichi and Mikoshiba 1995; 
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characterization of ion channels (gating, conductance, 
selectivity, etc) cannot be ascertained (Jonas et al 1997). 
Intracellular patch-clamping is a technique in its infancy. 
In the future, advances in both recording hardware and 
computer software are likely to advance our understanding 
of intracellular ion channels in general, and Aβ induced 
channels in particular.
A selection of literature that supports Ca2+ ion perturba-
tion as a central aspect of AD pathology is presented:
1.  The levels of the calcium binding protein calsenilin are 
elevated in the cortex of AD patients. This is also noted in the 
neocortex and hippocampus regions of βAPP mutant trans-
genic mice as well as neurons in culture (Jo et al 2004).
2.  In neurons that are burdened by PHF, increases in Ca2+-
dependent proteases and Ca2+-activated kinases have been 
demonstrated (Xiao et al 1996; Grynspan et al 1997).
3.  In both familial and sporadic forms of AD as well as trans-
genic animal models of the disease, disruptions of Ca2+ 
homeostatic mechanisms have been reported (Eckert et al 
2001).
These are very selective examples of a fast growing 
body of literature that unambiguously implicates Ca2+ and 
its cellular regulation in AD pathogenesis (Mattson et al 
1992). In addition Mattson’s group have clearly shown 
that the aggregation state of Aβ and loss of neuronal Ca2+ 
homeostasis are directly related (Mattson et al 1993). 
This last point is an important one for the purpose of 
this review since it lays the foundation for examining 
the ion channel hypothesis of AD pathophysiology in 
greater detail.
Aβ toxicity as a result
of the formation of abnormal ion 
channels
Shortly after Mattson et al and Hardy et al had reported 
perturbed neuronal Ca2+ homeostasis under the inﬂ  uence 
of Aβ, Nelson Arispe ﬁ  rst reported that Aβ formed ion 
channels in model membranes (Hardy and Higgins 1992; 
Mattson et al 1992; Arispe et al 1993). The hypothesis 
that Arispe et al tested was based, principally on Mattson 
and Hardy’s reports of disturbances in Ca2+ homeostasis. 
Brieﬂ  y, certain conditions or triggers (eg, genetic inﬂ  u-
ences, aging, etc) predispose APP proteolysis to produce 
more Aβ1–42 fragments. This peptide can oligomerize and 
insert into the cell membrane as a cation-selective ion 
channel. These channels allow unregulated Ca2+ movement 
into the cell leading to a breakdown of ionic homeostasis 
(see below).
Calcium ion alterations induced
by Aβ
Since Ca2+ is critical to cell function and therefore tightly 
regulated, disorders or disruptions in the Ca2+ signaling 
machinery of the neuron has many deleterious conse-
quences. One of the earliest reports in the literature that 
demonstrated Ca2+ toxicity with reference to AD, was by 
Hardy and Higgins. These researchers reported that Aβ 
disrupted Ca2+ homeostasis and increased [Ca2+]i (Hardy 
and Higgins 1992). Further conﬁ  rmation of this idea was 
provided by Young et al (1986) who reported that [Ca2+]i 
rose when Aβ was applied to neurons in culture. In an 
attempt to explain these ﬁ  ndings, Nelson Arispe’s group 
posited a new hypothesis basing it on the assumption 
that Aβ peptides could be forming Ca2+ conducting chan-
nels in cell membranes. This would readily explain Ca2+ 
anomalies reported by Hardy et al. They tested the idea 
rigorously and published their ﬁ  ndings in 1993. Arispe and 
colleagues created a de novo planar bilayer of palmitoy-
loleolylphosphatidylethanolamine and phosphatidylserine 
in a plexiglass chamber where channel currents could be 
recorded across the membrane. In this setup, when mil-
limolar concentrations of Aβ1–40 were applied to the mem-
brane, discrete channel currents were consistently observed 
within minutes. Standard electrophysiological techniques 
(such as an analysis of reversal potentials) suggested that 
the Aβ peptide formed cation-selective channels and that 
at transmembrane potential negative to –4 mV, Ca2+ moved 
across the membrane and the kinetics of this translocation 
was consistent with transport through a Ca2+ channel. These 
data were very compelling and heralded subsequent work by 
many other investigators who validated the phenomenon of 
ion ﬂ  ow (especially Ca2+) across artiﬁ  cial membranes under 
the inﬂ  uence of Aβ (Arispe et al 1993) (see below).
The Aβ ion channel hypothesis tested
Soon after publishing data on ion ﬂ  ow in artiﬁ  cial membranes, 
Arispe collaborated with the Pollard and Rojas group at the 
NIH. Together, these investigators modeled the molecular 
structure of Aβ ion channels. This mathematical/computer 
simulation theorized that Aβ could form ion channels if it 
assembled into subunits. Alone, a single Aβ peptide sequence 
could not be visualized to form an ion pore given the relatively 
large conductances that had been observed in empirical 
data (5 nS) and the relatively small size of Aβ (about 40 or 
42 amino acids) (Durell et al 1994) The model suggested 
that oligomeric Aβ subunits could form an ionophore-like 
assembly that closely resembled native cation channels.Neuropsychiatric Disease and Treatment 2007:3(5) 606
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In 1997 Sanderson and Ingram reported that at micromo-
lar concentrations, Aβ25–35 could induce voltage-gated Ca2+ 
currents in the hNT human teratoma cell line. This was an 
odd ﬁ  nding because of the different Aβ isoform that was 
used (25–35 rather than 1–42 or 1–40) and that the authors 
were interpreting their results to show voltage-gating. This 
is difﬁ  cult to reconcile since the current understanding of ion 
channel voltage sensors is that they are structures formed by 
pore loops and the S4 transmembrane segment of channel 
subunits (Bezanilla 2000). An analogous structure has not 
been shown in Aβ channels or channel models. Despite these 
caveats the Sanderson paper is still an important one because 
it suggests that channel pore formation might not be limited 
to only one isotype of Aβ.
In 1997, Arispe and his colleagues further added to data in 
support the of the “Aβ ion channel” paradigm. In an immor-
talized human hypothalamic cell line (GT1–7), they used the 
patch-clamp technique to record currents under voltage-clamp 
conditions. Aβ1–40 and the reverse sequence 40–1 were both 
tested in these experiments. Only Aβ1–40 was demonstrated 
to form cation-selective channels in this cell type. In the 
previous year (1996), Arispe had already reported that Aβ 
channel activity could be modulated by Zn2+. Speciﬁ  cally, 
Zn2+ altered channel kinetics (at 250 μM concentrations) and 
blocked channel activity at higher concentrations (Arispe 
et al 1996). Subsequently, these investigators were also able 
to show that Zn2+ could block (Aβ) channel currents when 
applied to the intracellular face of the cell membrane. This 
fact was a strong argument in favor of discrete channel for-
mation since such blockade was only thought possible by the 
metal ion physically obstructing a channel pore (Kawahara 
et al 1997). In 1998, Seung and Lal reported on a collabora-
tion between the University of California at Santa Barbara 
and Yeungnam University in Korea. These authors looked 
at Aβ1–42 activity in reconstituted phospholipid vesicles and 
found that when the vesicles were reconstituted with Aβ1–42, 
there was a 4-fold increase in radio-labeled Ca2+ and this was 
prevented in the presence of Tris and, most interestingly, Zn2+ 
(Rhee et al 1998). Zn2+ however, was not the only reported 
channel blocker in these and similar experiments reported 
by others. Bruce Kagan’s lab at the University of California 
Los Angeles published ﬁ  ndings in planar bilayers that both 
Aβ1–40 and Aβ1–42 induced cationic currents and these were 
not only blocked by Zn2+ but also by the diazo dye, congo red 
(Hirakura et al 1999). These results were further conﬁ  rmed 
by Lal’s group in 1999 (Lin et al 1999). The next year, Bha-
tia and Lal further tested Aβ1–40, 1–42 and 25–35 in cultured 
endothelial cells. Even in this cell system, the Aβ ion channel 
idea was reinforced. In this study, Aβ1–42 was shown to cause 
morphologically proven cellular degeneration more readily 
than the other isoforms and that this effect was concentra-
tion dependent. This was also dependent on the presence of 
Ca2+. As predicted, micromolar amounts of Zn2+ afforded 
protection from peptide induced cell damage in the study 
(Bhatia et al 2000).
In recent years, more and more work appears to sub-
stantiate the data of the 1980s and 90s. For example, data 
showing an increase in [Ca2+]i in a phaeochromocytoma 
cell line (PC12) by nanomolar concentrations of Aβ25–35 
have been published. This effect was reported to be depen-
dent on extracellular Ca2+ levels. Using a variety of classic 
Ca2+ channel blockers as well as other compounds, these 
authors effectively argued that the rise in [Ca2+]i was 
through Aβ induced channel pores and not secondary to 
Ca2+ entry through L-type or ligand-gated channels (Huang 
et al 2000). In reconstituted planar lipid bilayers, Lin and 
Lal reported that Aβ1–42 formed oligomeric channel like 
structures (visualized by atomic force microscopy). They 
further reported that at physiologic nanomolar concentra-
tions Aβ1–42 caused neurite loss in mouse neuroblastoma cells 
and at micromolar levels this effect was ampliﬁ  ed and led 
to cell death. Their argument was strengthened by experi-
ments where Ca2+ dependence of these Aβ1–42 effects was 
compellingly demonstrated and protection by the presence 
of Zn2+ was also established (Lin et al 2001).
In 2003 Bahadi et al added Cu2+ to the growing list of sub-
stances that could signiﬁ  cantly modulate the currents induced 
by Aβ. Again working with reconstituted artiﬁ  cial membranes 
as well as liposomes, this group reported that 150 μM of Cu2+ 
could block outward currents quite effectively (Bahadi et al 
2003). In 2004, Arispe reported that Aβ1–40 induced currents 
in lipid bilayers could be blocked by speciﬁ  c peptides that 
had been designed to block the pore region of the Aβ chan-
nel. In this novel paper, Arispe et al designed simple peptides 
that conformed to the Aβ oligomeric structure of ion channel 
models (speciﬁ  cally, the pore region). These peptides were 
typically only 7–11 residues in length and required relatively 
simple protein chemistry equipment to synthesize. Several of 
these in-house manufactured proteins were tested in Arispe’s 
laboratory and some were found to block channel currents. 
One of several peptides that were tested (designated NA4 by 
the authors) proved to be the most effective blocker of chan-
nel currents. This series of experiments lent strength to the 
hypothesis that Aβ could insert into planar bilayers and form 
channel-like pores whose structure could be predicted and 
activity blocked by speciﬁ  c peptides (Arispe 2004). Arispe Neuropsychiatric Disease and Treatment 2007:3(5) 607
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has continued to publish data in support of the ion channel 
hypothesis even more recently. For example, in 2006 his 
lab has investigated Aβ’s toxic effects in cultured cell lines 
(PC12) with particular reference to apoptosis. His ﬁ  ndings can 
be summarized as follows: (i) increase in [Ca2+]i by nanomolar 
concentrations of Aβ1–42; (ii) blockade of this effect by NA4 
[Arispe’s previously designed Aβ channel blocking peptide]. 
The creation and testing of several “blocking peptides” in 
this study was based on the hypothesis that if Aβ was form-
ing channel-like structures on artiﬁ  cial membranes, then 
complimentary peptide sequences of adjacent Aβ subunits 
in this channel-like structure would interact with each other 
and that these would also interact with synthesized peptide 
sequences designed to complement those on the subunits. 
Several different peptides were tested in these experiments; 
(Arispe 2004)]; (iii) increased permeability of PC12 cell 
membrane when exposed to Aβ1–42; (iv) retention of Aβ1–42 on 
cell surface even after the cell culture medium (that initially 
introduced the peptide) was removed. This suggested stable 
insertion of Aβ in the membrane, possibly as an ionophore; 
(v) reversal of toxic effects to the cells upon removal of Aβ1–42 
(Simakova and Arispe 2006).
The basic conﬂ  ict in literature which supports the “ion 
channel” hypothesis is clear. The predominant evidence 
is indirect, is limited to in vitro systems and appears to 
implicate more that one isotype of amyloid β (the bulk of 
the evidence comes from studies that have used commer-
cially sourced, exogenous Aβ1–40). The gold standard of 
electrophysiological studies is the whole-cell, patch-clamp 
experiment. In the ideal sense, if neuronal cells could be 
isolated from relevant regions of the brain in AD animal 
models (especially a hypothetical one that would have a 
true AD phenotype) and all the native ion channels on such 
a hypothetical cell could be blocked without altering the 
physiology of the cell followed by recording ionic currents 
form these neurons under clamp conditions, one could expect 
empirical evidence that would be direct, widely accepted 
and most useful to the understanding of AD. This, however, 
remains an elusive goal. Table 2 summarizes important lit-
erature presenting data in support of Amyloid β ion channel 
formation and activity. As is clear from an overview of this 
body of literature, the experimental design, nature of model 
systems and results and conclusions of these studies is not 
consistent. Speciﬁ  c questions that are very critical have not 
been answered. For example, it is widely accepted that Aβ1–42 
is probably the only toxic entity or in the very least, is more 
toxic to neurons in AD. Its more abundant companion, 1–40, 
appears to contribute less or even not at all to AD neuronal 
damage and loss. Which of these has more ion channel 
forming capabilities?
If Aβ1–40 forms channels more readily then this would 
ostensibly ﬂ  y in the face of received wisdom that Aβ1–42 is 
more toxic. Why might certain cortical areas be prone to 
aberrant channel formation? APP is not unique to neurons or 
even to CNS. Why do its proteolytic products not manifest 
toxicity elsewhere? These questions have been posed by 
many but remain unanswered.
The counter argument
A strong argument against the idea of Aβ peptides form-
ing ion channels has emerged in very recent literature. 
James Hall’s laboratory at the University of California 
at Irvine and their collaborators at the NIH have reported 
that amyloid oligomers breakdown or significantly reduce 
the normal dielectric barrier in lipid bilayers. This is in 
sharp contrast to the ion channel idea because it implies 
that the plasma membrane might become “leaky” to 
cations and would then induce qualitatively the same 
effects as have been reported in recent years (Sokolov 
et al 2006). Sokolov’s interpretation of the data is that Aβ 
oligomers increase the conductance of lipid bilayers and 
this has been tested by both anionic as well as cationic 
probes. These investigators saw no single channel activity 
in their model. It is difficult to be compelled by a single 
set of experiments even though Sokolov’s experimental 
design is perfectly valid. However, more persuasive are 
the points the authors make in discussing the implica-
tions of their work. Quite correctly they identify the two 
major hurdles that obstruct wider acceptances of the Aβ 
ion channel hypothesis:
1.  The single channel currents that have been reported in Aβ 
literature must successfully predict the bulk conductance 
properties of neuronal membranes.
2.  Current blockade by various agents must also be validated 
in the context of whole membranes.
Neither of these two phenomena has been tested thus 
far. Therefore, the overall limitations of the evidence that 
has been published from many different groups working 
in parallel in several different institutions may be sum-
marized as:
1.  Much of the evidence that centers on the demonstration 
of single channel currents, have been recorded either in 
artiﬁ  cial membranes or in immortalized cell lines.
2.  Ionic conductances of bulk membranes have neither been 
predicted by single channel properties nor have these been 
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3.  In vivo experiments on cortical neurons in primary culture 
from some of the standard animal models of AD, could 
effectively demonstrate classical properties of cation-
selective ion channels. Such experiments have not been 
performed.
4.  Unequivocal evidence that the reversal of aberrant 
ionic ﬂ  ow (eg, with selective channel blockers) through 
hypothesized Aβ ion channels can also attenuate the 
neuronal toxicity or prevent apoptosis or enhance cell 
survival in AD models has not been demonstrated.
5.  Clear demonstration of neuronal cell surface expression 
of oligomerized, channel forming Aβ in vivo has not 
been done.
Conclusion
The ion channel hypothesis of AD pathophysiology is a ratio-
nal extrapolation of many sets of data published over several 
decades. Collectively, the evidence suggests that amyloid β 
peptides cause neuronal degeneration and apoptosis in AD by 
inserting in a stable manner into the neuronal membrane as 
unregulated cationic channels. These abnormal channels ulti-
mately compromise ionic homeostasis of affected neurons.
There are several inherent challenges that will continue 
to confound investigators who pursue this direction in 
AD research. As discussed above, Aβ ion channels are an 
unproven phenomenon at this time. In many ways, it does 
or potentially can, predict the phenomena observed in the 
neuropathology of the AD brain. In order to strengthen the 
“ion channel hypothesis” investigators will have to overcome 
several distinct challenges. These are:
1.  Though there are many AD animal models, none are 
entirely satisfactory. For example, the large scale loss 
of neurons observed in human sufferers of AD has not 
been duplicated in transgenic models. Overall, a relatively 
modest degree of cell death has been observed in just 
one transgenic model (APP transgenic; ~14% neuronal 
loss) and this too was limited to the CA1 region of the 
hippocampus (Stalder et al 1999; Gotz et al 2004). In 
addition, the exact spatial and temporal sequence of 
plaque deposition and tangle formation has also not been 
duplicated with ﬁ  delity in these animals. Neuronal culture 
is the most accessible method of testing native neuronal 
populations and such experiments are not proximate 
simulations of what might be happening in the human 
AD brain. Furthermore, classic single-cell electrophysi-
ological experiments (ie, with the whole-cell patch-clamp 
technique) is challenging and best suited for studying 
native channel populations.
Table 2 Summary of selected key publications which support, directly or indirectly, the ion channel hypothesis of AD pathogenesis. 
Note relative dominance of in vitro systems and that the majority of studies utilized exogenous Amyloid β1–40
Citation Experimental system Aβ species Main conclusions
Arispe, Rojas and 
Pollard, PNAS, 
1993
Artiﬁ  cial membranes 1–40 Cation selective channel formation by exogenous Aβ 1, 40 application, 
recording of Ca2+ currents and blockade of these by Tromethamine 
and Al3+.
Whitson and Appel 
Neurobiol Aging, 
1995
Rat Hippocampal neuro-
nal culture
1–40 Neuronal survival assessed following exposure to exogenous Aβ1, 40. 
Diltiazem (Ca2+ channel blocker) attenuated toxicity of Aβ while other 
blockers did not.
Sanderson, Butler 
and Ingram, Brain 
Res, 1997
hNT Human teratocar-
cinoma (neuron-like) 
immortalized cell line
25–35  hNT cells displayed inward Ca2+ currents with exposure to μM con-
centrations of Aβ 25, 35.
Kawahara, Arispe, 
Kuroda et al 
Biophys, J 1997
Immortalized hypotha-
lamic neurons (GT1–7)
1–40 Formation of cation channels were seen after application of Aβ1, 40. 
Zn2+ blocked these channel currents
Rhee, Quist and 
Lal, J Biol Chem, 
1998
Synthesized liposomes 
with Aβ1, 42 incorpo-
rated
1, 42 Large inﬂ  ux of Ca2+ seen in liposomes constituted with Aβ1, 42. Effect 
was blocked by Tris and Zn2+.
Hirakura, Lin and 
Kagan, J Neurosci 
Res, 1999
Planar lipid bilayers 1–42 and 1–40 Both species induced currents which were cation selective and were 
blocked by Zn2+ and Congo Red.
Lin, Bhatia and Lal, 
FASEB J, 2001
Planar lipid bilayers 1–42 Atomic Force Microscopic (AFM) evidence of multimeric structures 
formed in planar lipid bilayers under the inﬂ  uence of Aβ1-42. Aβ1-42 
induced neuritic degeneration and neuronal death and these effects 
were blocked by Zn2+.
Arispe, J Memb 
Biol, 2004
Planar lipid bilayers 1–40 Cation-selectivity observed in ionic currents recorded from lipid 
bilayers were blocked by custom made peptides designed to block the 
putative channel pore.
Quist, Duodevski, 
Lin et al PNAS, 
2005
Planar lipid bilayers 1–40 Aβ 1–40 induced ionic currents in planar lipid bilayers. AFM evidence 
for channel-like structures in these structures when exposed to 
Aβ1–40.Neuropsychiatric Disease and Treatment 2007:3(5) 609
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2.  Electrophysiological studies in neurons in culture are 
technically demanding and similar experiments on sub-
cellular structures is only at a nascent stage and needs 
further development (Hamill et al 1981; Mazzanti et al 
1990; Keller and Hedrich 1992; Ehrlich et al 1994; Jonas 
et al 1997).
3.  In studies that have been detailed in this review, the meth-
odology involved dissolution of Aβ in water. Dissolved 
monomeric peptide is then added to solutions bathing 
lipid bilayers (in setups modiﬁ  ed from patch-clamp 
ampliﬁ  ers and equipment). Alternatively, the peptide is 
sonicated in the presence of lipids to form proteolipo-
somes which are then fused into the bilayer. In addition 
different peptide fragments are used and the consequent 
variability of data between laboratories should not be 
surprising.
4.  The required proof of establishing abnormal ion channels 
is necessarily stringent. The literature claims that these 
channels are cation selective and can be blocked. Carrying 
the concept from artiﬁ  cial membranes to living cells is the 
required step that needs to be carefully and consistently 
demonstrated. The criteria for identiﬁ  cation might ﬂ  ow 
through the following scheme:
 a.      Identiﬁ  cation of single channel currents in relevant 
model systems.
  b.    Testing the channel in a heterologous system, such 
as Xenopus.
  c.    The use of advanced techniques such as reverse 
genetic approaches and nucleic acid microarray 
methods to modulate the behavior of these putative 
structures.
Despite these daunting obstacles, in our opinion, there is 
a clear advantage in pursuing the “Aβ ion channel hypoth-
esis” because if validated it has the potential of providing an 
innovative framework upon which AD therapy, especially 
through pharmacological means, can be designed. Currently 
the only approved treatments for AD are either cholinesterase 
inhibitors (such as Aricept®) or the glutamate antagonist, 
Memantine®. At best these are quite limited in their efﬁ  cacy to 
halt or attenuate the progression of Alzheimer’s dementia.
There has been enthusiastic interest in a new phar-
maceutical strategy in AD treatment. These are drugs 
that directly attenuate Amyloid β levels in brains of AD 
patients. Two of these compounds are now in phase III 
trials. R-FLURBIPROFEN, one of these, is a single enan-
tiomer of the NSAID, Flurbiprofen. Although this molecule 
lacks any activity against COX (cyclooxygenase), it is 
a potent attenuator of Amyloid β (2005 Mar). The other 
compound is TRAMIPROSATE (ALZHEMED™). In the 
brain, interaction between Amyloid β and proteoglycans 
promotes tissue deposition of the peptide. Tramiprosate 
(3-amino-1-propane-sulfonic acid) was developed as a 
glycosaminoglycan (GAG) mimetic that would interact 
with the GAG-binding region of Aβ thereby antagonizing 
ﬁ  brillation. This compound is also in phase III trials (Aisen 
2005). Another compound that is generating interest is the 
γ-secretase inhibitor, LY450139. This drug is in Phase II 
trials. In 2004, working with this compound, Gitter and 
colleagues demonstrated that LY450139 was a potent, 
stereoselective inhibitor of Aβ secretion in SWEAPP293 
cells (derived from a HEK cell line which overexpressed 
APP carrying the Swedish mutation, SWEAPP293). In this 
system, LY450139 was seen to inhibit Aβ via antagonism 
of γ-secretase activity (Gitter et al 2004). If successful in 
trials, drugs like LY450139 have signiﬁ  cant potential to 
mature into novel treatments of AD and provide additional 
evidence that the Aβ neuronal load is the direct cause of 
dementia in this disorder.
AD remains a disease with an increasing health care burden 
on the US economy. The Alzheimer’s Association reports that 
5 million Americans are currently afﬂ  icted (of a total population 
of 300 million) and AD and other dementias impact the economy 
to the tune of some $148 billion annually by 2007. Therefore 
any investment of ﬁ  nancial or intellectual resources in this area 
of AD investigation is very likely to pay dividends.
It is also possible that the ion channel hypothesis is 
either ﬂ  awed or limited in its scope. In other words, AD 
is either completely unrelated to abnormal ion channels or 
ionic ﬂ  ow (the Sokolov paper in 2006 is a case in point) or 
these anomalies only play a minor role in the mechanism 
of neuronal degeneration or dysfunction. If the hypothesis 
remains unproven or is further challenged by contradictory 
data, it is likely that such a shift in paradigm might unravel 
the mystery of Aβ toxicity to the extent that an effective 
treatment of AD becomes a reality.
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